January 21, 2014

Par Pharmaceuticals Cos. on Tuesday announced that it entered into an agreement to acquire JHP Group Holdings, parent company of JHP Pharmaceuticals.

January 17, 2014

Par Pharmaceutical on Thursday announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin (digoxin) tablets.

July 18, 2013

The Food and Drug Administration has approved a cholesterol drug made by Par Pharmaceutical Cos., the drug maker said Thursday.

April 21, 2013

Last month, the Supreme Court heard Federal Trade Commission v. Actavis, which could impact the future of the generic drug industry at a time when 80% of all prescriptions dispensed in the United States are generic.

February 28, 2013

The battle over "pay for delay" continues to heat up, and its resolution likely won't come until the nation's highest court decides on the legality of the practice.

January 3, 2013

Par Pharmaceutical Cos. has started shipping two formulations of a generic drug for treating migraines, the company said.

December 18, 2012

Drug maker Merz Pharmaceuticals is suing Par Pharmaceutical over the latter's attempt to market a generic drug for cerebral palsy patients, according to published reports.

December 6, 2012

Par Pharmaceutical Cos. has contracted with AstraZeneca to distribute an authorized generic version of a drug used to treat high blood pressure, Par said.

November 29, 2012

Patent settlements between generic and branded drug companies seem like one of the most controversial and long-standing issues in the pharmaceutical world, with strong opinions on both sides.


November 29, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

November 5, 2012

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis.

October 25, 2012

The Food and Drug Administration has approved a generic drug for leukemia made by a subsidiary of Par Pharmaceutical Cos.

October 16, 2012

The Federal Trade Commission has voted to approve Watson Pharmaceutical's acquisition of Switzerland-based generic drug maker Actavis.

October 16, 2012

Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.

September 18, 2012

Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.


April 23, 2012

Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

April 6, 2012

Par Pharmaceutical has started shipping its generic version of a drug for sleep disorders, the company said Friday.

April 5, 2012

Teva is the first company to file for a generic version of a drug to treat sleep disorders, the Food and Drug Administration has determined.

February 24, 2012

Generic drug maker Par Pharmaceutical has completed its acquisition of an Indian drug company, Par said.

December 5, 2011

Following the settlement of a patent-litigation suit with Swiss drug maker Novartis over the patch Vivelle-Dot (estradiol transdermal system), a drug for treating symptoms of menopause, Mylan said it had received a patent license to begin selling its version of the drug in December 2013.


November 22, 2011

Generic drug maker Par Pharmaceutical has promoted Thomas Haughey to president and Paul Campanelli to COO, the company said. The promotions take effect immediately.

November 18, 2011

Par Pharmaceutical has completed its acquisition of Anchen Pharmaceuticals, the generic drug maker said.

September 12, 2011

The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO.

August 24, 2011

Par Pharmaceutical Cos. will acquire Anchen Pharmaceuticals for $410 million, Par said Wednesday.